Business Context and Reporting Period
Oaktree Specialty Lending Corp (OCSL) is a closed-end, externally managed Business Development Company (BDC) regulated as a Regulated Investment Company (RIC). The company provides customized credit solutions, including first and second lien loans, mezzanine loans, and preferred equity, primarily to middle-market companies. As of October 17, 2017, the company has been managed by Oaktree Capital Management, L.P. This filing covers the quarterly period ended March 31, 2019, and the six months ended March 31, 2019.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2019 | Six Months Ended Mar 31, 2019 | Three Months Ended Mar 31, 2018 | Six Months Ended Mar 31, 2018 |
|---|---|---|---|---|
| Total Investment Income | $38.2 million | $76.5 million | $34.8 million | $68.7 million |
| Net Investment Income | $17.7 million | $35.0 million | $15.3 million | $28.6 million |
| Net Realized Gains | $25.2 million | $43.2 million | $4.9 million | $4.6 million |
| Net Unrealized Appreciation | $21.5 million | $14.5 million | $(0.4) million | $(43.8) million |
| Net Increase in Net Assets from Operations | $64.5 million | $92.2 million | $19.6 million | $(10.8) million |
| Earnings Per Share (Basic & Diluted) | $0.46 | $0.65 | $0.14 | $(0.08) |
| Net Asset Value (NAV) per Share | $6.55 | $6.55 | $5.87 | $5.87 |
| Total Assets | $1.54 billion | $1.54 billion | $1.55 billion | $1.55 billion |
| Total Liabilities | $617.9 million | $617.9 million | $693.4 million | $693.4 million |
| Net Assets | $923.5 million | $923.5 million | $858.0 million | $858.0 million |
| Cash and Cash Equivalents | $12.8 million | $12.8 million | $13.4 million | $13.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Total investment income increased by 10.0% for the quarter and 11.5% for the six-month period compared to the prior year. This was driven primarily by an increase in interest income due to OID accretion (specifically related to Dominion Diagnostics, LLC) and higher LIBOR rates, partially offset by lower fee and dividend income.
- Realized Gains: Net realized gains surged to $25.2 million for the quarter and $43.2 million for the six months, compared to $4.9 million and $4.6 million in the prior year periods. Significant gains were realized from the full exits of Maverick Healthcare Group, LLC and Comprehensive Pharmacy Services LLC.
- Unrealized Appreciation: The company recorded net unrealized appreciation of $21.5 million for the quarter and $14.5 million for the six months, a significant improvement from net unrealized depreciation of $0.4 million and $43.8 million in the prior year periods.
- Debt Repayment: The company fully repaid its $228.8 million in 2019 Notes during the quarter ended March 31, 2019. Concurrently, borrowings under the ING Facility increased from $241.0 million to $424.8 million.
- Portfolio Composition: As of March 31, 2019, 78.9% of the portfolio at fair value consisted of senior secured debt, and 14.4% consisted of subordinated notes. The portfolio was invested in 110 portfolio companies.
Guidance, Outlook, and Risks
- Management Commentary: Management continues to reposition the portfolio into investments aligned with Oaktree's credit investing approach, aiming to rotate out of non-core investments. The company targets a debt-to-equity ratio of 0.70x to 0.85x.
- Asset Coverage: The Board approved the application of reduced asset coverage requirements (150% instead of 200%) under Section 61(a)(2) of the Investment Company Act, effective February 1, 2020, subject to stockholder approval. This change is expected to reduce the base management fee on assets financed with leverage above 1.0x debt-equity to 1.00%.
- Brookfield Transaction: Oaktree Capital Group (OCG) entered into a merger agreement with Brookfield Asset Management. While Oaktree's management expects to continue operating independently, the transaction is subject to closing conditions and regulatory approvals.
- Risks and Contingencies:
- Credit Risk: Six investments were on cash or PIK non-accrual status as of March 31, 2019, representing 10.61% of the debt portfolio at cost. Notable non-accrual investments include Dominion Diagnostics, LLC and Cenegenics, LLC.
- Interest Rate Risk: 86.3% of the debt portfolio at fair value bears floating interest rates. A 100 basis point increase in rates would result in a net increase in operations of approximately $7.6 million annually.
- Liquidity: The company has $95.1 million in unfunded commitments as of March 31, 2019.
Key Facts for Investor Verification
- NAV vs. Market Price: Verify the current market price of OCSL shares relative to the reported NAV of $6.55 per share to assess the discount or premium.
- Non-Accrual Portfolio: Review the status of the six investments on non-accrual status (including Dominion Diagnostics and Cenegenics) and the potential impact on future income and principal recovery.
- Fee Waivers: Note that the company accrued $7.9 million in potential fee waivers for the quarter, including a full waiver of the capital gains incentive fee, which impacts net expense calculations.
- Debt Structure: Confirm the terms of the amended ING Facility (increased to $680 million, extended maturity) and the impact of the reduced asset coverage ratio on future leverage capacity and management fees.
- Realized Gains Sustainability: Assess whether the significant realized gains from specific exits (Maverick Healthcare, Comprehensive Pharmacy) are indicative of a trend or one-time events.